India’s Sun Pharma to acquire U.S.-based Concert for $576 mln
Jan 19 (Reuters) – Sun Pharmaceutical Industries Limited (SUN.NS) said on Thursday it will acquire U.S.-based Concert Pharmaceuticals (CNCE.O) for $576 million in cash to gain access to an experimental drug for treating patchy baldness.
Concert’s lead candidate, deuruxolitinib, is being evaluated as a treatment for autoimmune condition alopecia areata, which results in patchy hair loss.
India’s Sun Pharma said it will commence a tender offer to acquire Concert at $8 per share, a premium of 16% to the stock’s last close.
Concert stockholders will also receive a contingent value right entitling them an additional amount of up to $3.50 per share of common stock in cash, contingent on sales milestones.
Our Standards: The Thomson Reuters Trust Principles.